Unit 1 Flashcards

1
Q

Pharmacology

A

the study of the interactions of drugs (chemical substances) with biological systems

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

MEC = ?

A

Minimum Effective Concentration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Therapeutic window

A

difference in plasma concentration [Cp] between the desired and adverse response MEC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Pharmacodynamics

A

what the drug does to the body (mechanism of action)

-identifies drug target

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Pharmacokinetics

A

what the body does to the drug

absorption, distribution, elimination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Bioavailability (F)

A
  • how much drug reaches its target in the body
  • Used for adjustment of dose when route is changed and when designing dosage regimens

F = AUC oral/AUC iv (%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Time to peak (Tmax or Cmax)

A

how fast the drug reaches the target in the body

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Volume of distribution (Vd)

A

what dose necessary to obtain desired plasma concentration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Absorption is the process of getting the drug from ______ into __________

A

site of administration (past membranes)

into the blood stream

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Distribution is the process of getting the drug from ___________ to ________

A

bloodstream to intended target in tissues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Elimination

A

metabolism/excretion to eliminate drug activity after drug administration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Duration of action (aka ?)

A

aka half life

how long will the drug stay at its target and exert clinical effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Factors that determine a drug’s ability to cross biological membranes (4)

A

1) Molecular size (small MW = better absorption)
2) Lipid solubility (more lipid soluble = cross membrane better)
3) Degree on ionization (more unionized = more lipid soluble = more absorption)
4) Concentration gradient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Mechanisms by which drugs can cross biological membranes (3)

A

Passive diffusion
Carrier mediated diffusion
Endocytosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Passive diffusion of drugs can occur via… (2)

A

1) Aqueous diffusion/filtration of drug through aqueous channel (size dependent)
2) crossing lipid membranes via hydrophobic interactions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Carrier mediated diffusion of drugs can occur via… (2)

A

1) Facilitated diffusion driven by concentration gradient (no energy required)
2) Active transport - energy dependent, selective, saturable, unidirectional, for drugs which resemble endogenous compound

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Enteral routes of drug administration occur via the ________ and include _______ and ________

A

GI tract

Oral and rectal administration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Oral drug administration bioavailability = ?

Depends on _______ , _________ and ___________

A

0-100%

Depends on:

1) survival in GI environment
2) ability to cross GI membrane
3) Efficiency of drug metabolism by gut wall or liver (first pass)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Oral drug administration rate of onset?

A

SLOW (15-30 minutes for immediate release)

Slower (hours) for enteric/sustained release

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Most common drug absorption for oral administration is via ________, favoring ___________ drugs

A

passive diffusion

lipophilic, nonionized drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Rate of absorption of drug is higher in _______ than in ________

A

small intestine than in stomach

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

When your stomach is empty you have ________, which increases ________

A

increased GI motility

increases absorption

= drunk chicks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Enteric drug coat acts to…

A

protect stomach from irritation and protects drugs from low stomach pH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Controlled-release prep pros and cons

A

pros: fewer administrations, increased compliance, overnight therapy, elimination of peaks/troughs
cons: greater inter-patient variability in cytoplasmic concentration, and formulation could fail giving patient entire dose (dose dumping)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Rectal drug administration bioavailability?

A

variable, but generally greater than oral because first pass metabolism is less for rectal compared to oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Rate of onset for rectal drug administration

A

not rapid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

IV drug administration bioavailability and rate of onset?

A

F = 100%

MOST RAPID onset (along with gas inhalation)
sec to min onset

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Sublingual/Buccal drug administration bioavailability and rate of onset?

A

F is generally high

Rate of onset = within minutes 5-10 min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Intramuscular (IM) drug administration bioavailability and rate of onset?

A

F = approaches 100%

Rate of onset: 5-10 min for aqueous solution, but slower for depot form

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Subcutaneous drug administration bioavailability and rate of onset?

A

F = approaches 100%

Rate of onset: 5-10 min for aqueous solution, but slower for depot form

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Inhalation (gaseous) drug administration bioavailability and rate of onset?

A

F = about 100%

Rate of onset: MOST RAPID (with IV),

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Inhalation (suspension) drug administration bioavailability?

A

F = variable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Transdermal (systemic) drug administration rate of onset?

A

slow (hours)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Sublingual/Buccal administration bypasses _________ and is best for ________ and _______ drugs

A

hepatic first pass metabolism

best for lipid soluble, potent (

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

IV drug administration

A
  • Most direct route, bypass all absorption barriers
  • Accurate and fast drug delivery, used for drugs with narrow therapeutic window
  • Most hazardous route b/c easy to reach irreversible toxic levels quickly, duration= t1/2 dependent
  • Higher chance of infection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

IM drug administration is used instead of subQ if __________

A

drug is too irritating for subQ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Cons of IM drug administration

A
  • pain, tissue necrosis, microbial contamination
  • absorption can be erratic/incomplete when solubility is limited
  • absorption/onset effected by blood flow/muscle activity at site of injection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Cons of subcutaneous drug administration

A

volume of dose is limiting

only for non-irritating drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Gas inhalation is used for…

A

rapid onset of SYSTEMIC drug effects, rapid rate of absorption due to high SA and blood flow in pulmonary tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Suspension inhalation is used for…

A

local topical effects, applied at site of action in lung (reduces systemic effects)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Transdermal drug administration

A
  • Prolonged drug levels, extended duration of action (24h, 3d, 7d)
  • 1st pass metabolism is avoided
  • Drug must be potent (dose ˂2 mg)
  • Must permeate skin w/o irritation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Topical/Dermal drug administration

A

Localized application via skin/mucous membrane (vaginal, nasal, eye) for tx of local conditions

  • Minimal systemic absorption
  • In children potential for 3-fold greater system availability that in adult (body SA: weight is greater)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Highest bioavailability of substances if…

A

largely hydrophobic, yet soluble in aqueous in solutions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

How handsome is Taylor on a scale from 1-10?

A

He exceeds the scale, trick question*

*High yield on USMLE Step I

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Which form of weak acids/bases are more readily absorbed?

A

Unionized

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Acids are trapped in _____

A

basic solutions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Bases are trapped in

A

acidic solutions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Which form of acid and base predominates if pH

A

protonated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Which form of acid and base predominates if pH>pKa

A

deprotonated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

_____ of urine can trap aspirin (weak acid) in overdose situations

A

alkalinization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Greater potential to concentrate _____ drugs in more acidic breast milk

A

Basic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Factors that influence drug distribution (3)

A

i. Anatomic barriers (molecular size, lipid solubility, degree of ionization, concentration gradient)
ii. pH of compartment (important for weak acid/weak base drugs)
iii. Protein binding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Relationship between tight junctions and drug distribution

A

Tight junctions between cells: limit movement of some drugs, requires passage through lipid membrane

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Tight junctions are present in (4)

A

GI mucosa, Blood Brain Barrier (BBB), placenta, renal tubules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

How does drug binding to plasma proteins effect drug distribution? (4)

A

i. Reduces concentration of active free drug
- Limits fetal exposure to drugs – pregnant women given drugs highly protein bound
ii. Hinders metabolic degradation and reduces excretion
- Decreases elimination rate and INCREASES half-life
- Acts as circulating drug reservoir  prolongs drug action
iii. Decreases volume of distribution (most of drug in plasma)
iv. Decrease ability to enter CNS through BBB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

Drug binding to plasma proteins can be of clinical significance if: (4)

A

displaced drug has narrow therapeutic index, displacing drug is started in high doses, Vd of displaced drug is small, or if response to drug occurs more rapidly than redistribution

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

Describe protein binding/ displacement drug-drug interactions

A

i. Displacement of 1st drug from protein binding site by 2nd drug results in increased levels of unbound 1st drug, but levels of total drug are unchanged because administration is unchanged

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Bolus toxicity

A

slow distribution out of plasma compartment can lead to toxicity for drugs given IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Formula for Vd using: amount of drug in body (Ab) and concentration of drug in plasma (Cp)

A

Vd = amount of drug in body (Ab) / concentration of drug in plasma (Cp)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

Volume of distribution

A

size of compartment necessary to account for total drug in body if present at SAME concentration in body as in plasma (Cp)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

Vd will vary between patients depending on: (3)

A

i. Body size – units of L/kg – calculated based on weight
ii. Composition (fat vs. lean)
iii. Changes in protein binding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

Calculate loading dose (LD) using Cp and Vd

A

*LD = Cp (desired) x Vd

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Calculate Cp using dose and Vd

A

Cp = D (mg) /Vd (L/kg)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

What would happen if the body relied solely on renal excretion to eliminate drugs without drug metabolism?

A

If only terminated by renal excretion, duration of action would be prolonged

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

Primary site of drug metabolism

A

Liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

% of drugs metabolized by the lungs

A

30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

% of drugs metabolized by the kidneys

A

8

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

% of drugs metabolized by intestines

A

6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

% of drugs metabolized by skin

A

1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

% of drugs metabolized by placenta

A

5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

CYP450 enzymes are located where?

A

membrane bound enzymes of the SER

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

During metabolism of drugs, lipid soluble compounds are converted to

A

more H20-soluble (more polar) compounds that are more readily excreted

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

Phase I reactions (3)

A
  1. Oxidation—CYP450 dependent or P450 independent (most common)
  2. Reduction (azo, nitro, carbonyl reductions)
  3. Hydrolysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

Phase II reactions (4)

A

Conjugations:

  1. Glucuronidation
  2. N-acetylation
  3. Glutathione conjugation
  4. Sulfate conjugation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

Phase I enzymes involved

A
  1. CYP450 (includes NADPH, flavoprotein NADPH-cytochrome P450 reductase, and O2) or non-CYP450
  2. Reductase
  3. Esterases or amidases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

Phase II enzymes involved

A
  1. Transferases (ie: glucuronyl transferases, N-acetyltransferases)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

Genetic polymorphisms Phase I?

A

Yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

Genetic polymorphisms phase II?

A

Yes (less)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

Test to detect polymorphisms for phase I metabolism

A

Amplichip test detects polymorphisms in CYP2D6 / 2C19 (metabolize antidepressants, antipsychotics, opioid analgesics)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

Age related changes in activity: phase 1

A

yes (decreases with age in 1/3 of patients)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

Age related changes in activity: Phase II

A

Yes (especially UGT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

Inhibitory/Inducibility: phase I

A

yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

Inhibitory/inducibility: phase II

A

Yes (less)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

Ease of saturability: phase I

A

minimal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

Ease of satuability: phase II

A

Substantial

Limited supply of endogenous unit provided by coenzyme  more easily saturable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

Characteristics of CYP450 (4)

A
  1. Substrate must be lipid-soluble (drugs, endogenous substances, etc. serve as substrates)
  2. Inducibile and inhibitable (by drugs)
  3. Postnatal development variable (neonates have 50-75% adult levels, BUT some drugs metabolized faster)
  4. Many different isozymes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

CYP3A4

A
  • does most phase 1 metabolism

- in gastric mucosa, NOT in large intestine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

Most drugs that are weak acids contain what functional group?

A

Carboxylic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

Most drugs that are weak bases contain what functional group?

A

Amino

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

CYP2D6

A

converts codeine to morphine

91
Q

an “Inducer” is a compound that causes ____________.

______ is the most common inducer

A

a qualitative (or quantitative) increase in activity

CYP450

92
Q

Mechanism of induction mainly due to __________ BUT also causes ________. The result is that induction has a ________ onset

A

increased synthesis of enzyme protein

decreased turnover

slow onset (48-72 hours)

93
Q

Therapeutic consequences of induction (3)

A

1) maximal effect seen in 7-10 days
2) causes pharmacokinetic tolerance (induction of drugs own metabolism)
3) Induction by one agent may increase clearance of another drug (drug-drug interactions)

94
Q

Oral contraceptives and Rifampin

A

Rifampin is an inducer that increases the clearance of oral contraceptives

95
Q

Inhibition of metabolism is…

Are phase I or phase II enzymes more prone to inhibition?

A

decrease clearance of drug by inhibiting drug metabolizing activity

Phase I

96
Q

4 mechanisms of metabolic inhibition

A

1) inhibit enzyme synthesis
2) competitive inhibitor (substrate competing for enzyme)
3) Allosteric inhibitor (not a substrate)
4) Inhibition due to formation of a metabolite that destroys the enzyme (suicide) or forms a tight complex stopping activity

97
Q

Lipitor and erythromycin

A

Erythromycin is an inhibitor of Lipitor clearance

98
Q

Inducer or inhibitor?

Phenobarbital [1A2, 2C9, 2C19, 3A4]

A

Inducer

99
Q

Inducer or inhibitor?

Phenytoin [2C9, 2C19, 3A4]

A

Inducer

100
Q

Inducer or inhibitor?

Carbamazepine [2C9, 2C19, 3A4]

A

Inducer

101
Q

Inducer or inhibitor?

Rifampin [1A2, 2C9, 2C18, 3A4]

A

Inducer

102
Q

Inducer or inhibitor?

Ethanol [2E1]

A

Inducer

103
Q

Inducer or inhibitor?

St. John’s Wort [3A4]

A

Inducer

104
Q

Inducer or inhibitor?

Tobacco smoke (not nicotine) [1A2]

A

Inducer

105
Q

Inducer or inhibitor?

Cimetidine [2D6, 3A4, 1A2]

A

Inhibitor

106
Q

Inducer or inhibitor?

Erythromycin / Clarithromycin [3A4]

A

Inhibitor

107
Q

Inducer or inhibitor?

Azole antifungals [3A4]

A

Inhibitor

108
Q

Inducer or inhibitor?

Fluoxetine (other SSRIs) [2D6,3A4]

A

Inhibitor

109
Q

Inducer or inhibitor?

Grapefruit juice [3A4]

A

Inhibitor

110
Q

Inducer or inhibitor?

HIV protease inhibitors [3A4]

A

Inhibitor

111
Q

Inducer or inhibitor?

Omeprazole [2C19]

A

Inhibitor

112
Q

P-Glycoproteins

A

Transporters that act primarily to move drugs OUT of the cell (varies based on location)

  • GI = decrease oral absorption of drugs
  • Liver-Kidney = enhance biliary and renal excretion of drugs
  • Blood-brain barrier = limits distribution of drugs to the brain
113
Q

Excretion is ________

______ are the most important organ for excretion, especially for _______ and ________ compounds.

A

-loss of chemically UNCHANGED drug from the body

  • Kidneys
  • water-soluble and non-volatile compounds
114
Q

Filtration in the kidneys

A

1) all drugs smaller than albumin (MW 69000) will be filtered
2) Only free drug is filtered

115
Q

Renal excretion is affected by renal ________ and ________

A

blood flow and function

116
Q

Active tubular secretion transports drugs from _____ –> ________ and occurs with drugs that are _________. This mechanisms is ________ and rate is NOT affected by ________

A

blood –> urine

strong acids and bases

saturatable, NOT affected by protein binding

117
Q

________ is a poorly developed process in neonates resulting in prolonged half life of some drugs

A

active tubular secretion

118
Q

Tubular reabsorption

A

i. Lipid-soluble, uncharged drugs can cross membrane → cleared at rate of urine formation (1ml/min)
movement based on concentration gradient

dependent on urine pH

ii. Primary function of drug metabolism → produce more water-soluble metabolite that is less likely to be reabsorbed.
iii. Active reabsorption: important for endogenous compounds (glucose, aa’s), most drugs REDUCE this active transport.

119
Q

Urine pH can be acidified by ________ or _______ and alkalinized by ________

A

NH4Cl or ascorbic acid

NaHCO3

120
Q

Enterohepatic Recycling

A

reduces the elimination of drug and prolongs its half life and duration of action in the body (keeps drug in the body, but out of systemic circulation)

Process:

Drug metabolites in liver (usually conjugates that increase MW to ˃300) secreted into bile
→ stored in gallbladder
→ small intestine via bile duct
→ hydrolyzed by bacterial enzymes back to the parent drug (more lipid soluble)
→ reabsorption from intestine into liver

121
Q

Therapeutic implications of Enterohepatic Recycling

A

i. Some drugs have a “reservoir” of re-circulating drug (morphine, ethinyl estradiol)
ii. Antibiotics can reduce gut bacterial flora and DECREASE enterohepatic recycling → DECREASE plasma drug levels = potential for drug-drug interaction (EX - estrogen)

122
Q

Breast Milk and drugs

A

most drugs cross (unchanged) into breast milk at LOW levels, BUT infant plasma level usually substantially below therapeutic level

123
Q

Breast milk is more ______ than plasma, so has a tendency to accumulate ________ compounds via ion trapping

A

acidic

basic

124
Q

Clearance

A

the volume of plasma (Vd) which is completely cleared of drug in a given period of time by the processes of kidney excretion and drug metabolism (and some minor others)

125
Q

Clearance equation and units

A

CL (mL/min) = Vd x Ke

126
Q

Half life

units?

A

time required to eliminate ½ of the drug amount

hours or minutes

127
Q

Half life is _______ of total amount of drug present (Cp)

A

independent

128
Q

Half life is dependent on both _______ and ______

A

clearance (increase clearance, decrease half life)

Volume distribution (increase Vd, increase half life)

129
Q

Time it takes a drug to be eliminated?

A

4-5 half lives

130
Q

Time it takes for a drug to reach steady state when administered continuously?

A

4-5 half lives

131
Q

Degree of fluctuation between doses (equation)

A

= 2^x, where x=# of t1/2 in dosage interval

132
Q

Virtually all drugs are eliminated via _______ kinetics when they are within __________.

A

first order

therapeutic doses

133
Q

First order kinetics: ______ is proportional to ________.

A

rate of elimination (mg/hr)

plasma concentration (Cp) (mg/L)

134
Q

Hepatic metabolism and renal excretion both use _________ kinetics

A

first order

135
Q

In first order kinetics, if the concentration of drug is doubled then the rate of elimination is…

A

doubled

136
Q

As drug is eliminated from the body, its concentration is __________, therefore, rate of elimination _________

A

constantly changing

also changes constantly

137
Q

When plotted graphically, Cp vs. Time, the slope of this line represents _________

A

the rate of elimination (decreases as Cp decreases when drug is eliminated)

138
Q

When plotted graphically, ln(Cp) vs time, the slope of the line represents _________

A

Ke (Rate constant of elimination)

139
Q

Elimination rate constant (Ke)

A
  • fraction of drug leaving body per unit time via all elimination processes.
  • CONSTANT
140
Q

Maintenance dose equation

A

CL = (Maintenance Dose / tau) / Cp

141
Q

Disstribution phase

A

initial curvlinear portion of graph - represents drug equilibrating between blood and tissue

142
Q

Half life equation

A

t 1/2 = 0.693 / ke

143
Q

Vd equation

A

Vd = Dose / Cp o (initial plasma concentration)

144
Q

Dose a bioavailability:

If oral F = 50% then to give the drug by IV you must…

A

times dose by 1/2

145
Q

Phase I drug metabolism does what?

A

inserts or unmasks functional group (OH, NH2, SH) on drug that renders molecule more water-soluble.

→Molecule can then undergo conjugation in Phase II rxn.

146
Q

Phase II drug metabolism does what?

A

endogenous substrate combines with pre-existing or metabolically inserted functional group on the drug forming a highly polar (water soluble) conjugate that is excreted via the urine.

147
Q

There are lab tests that can determine a person’s Warfarin metabolizing abilities by testing the activity of the warfarin metabolizing enzyme _______. Warfarin targets __________ enzyme.

A

CYP2C9

VKORC1 (Vitamin K reductase)

148
Q

First order elimination involves the elimination of a constant ________ of drug per unit time, where as zero-order elimination involves the limitation of a constant _______ of drug per unit time.

A

fraction (percent) - involves half lives

amount - does NOT involve half lives

149
Q

Zero-order elimination is most commonly observed for drugs that ___________.

A

saturate metabolic pathways when given in therapeutic doses (or drugs given at toxic doses)

150
Q

Hepatic clearance varies with…(3)

Low vs. high extraction drug?

A

1) Blood flow to liver
2) protein-drug binding
3) intrinsic hepatic metabolism (inducers and inhibitors)

  • low extraction drug (metabolism not efficient) changes do NOT significantly influence clearance
  • high extraction drug (metabolism efficient), changes will have a major influence on clearance
151
Q

Time to reach steady state plateau is related to _______ only and is independent of _______

A

drug half-life

drug dosage

152
Q

What effect will increasing maintenance dose have on time to reach steady state?

A

Increasing maintenance dose WILL NOT reach steady state sooner, will only cause Cpss to be higher when reached

153
Q

Effect of Loading Dose on steady state

A

Use Loading Dose to reach steady state faster

LD = Cp x Vd

154
Q

Zero order kinetics is most often due to saturation of ________ metabolic processes while _______ saturation is unlikely

A

hepatic

renal saturation unlikely

155
Q

Drug-Receptor Concept states that…

A

greater number of receptors occupied by drug = greater response provided

156
Q

Receptor (in Drug-Receptor Concept)

A
  • drug target, the sites of action in body that mediates pharmacologic effects of drugs
  • Specificity of fit of drug to receptor (recognition) induces conformational change in receptor protein.
157
Q

Consequences of Drug Receptor Theory (3)

A

1) Receptor mediates the actions of receptor agonists and antagonists
2) Receptors are responsible for selectivity of drug action
3) Theory allows determination of quantitative relation between dose or concentration of drug and its pharmacologic effects via use of dose-response curve

158
Q

3 Assumptions used with dose-response curves

A

1) Interaction follows simple mass action relationships
2) Binding is reversible
3) Response is proportional to receptors [R] occupied by drug [D]

159
Q

What shape is the dose-response curve?

A

Hyperbolic - confirms mathematical relationship between dose and response

e/Emax = [D]/ EC50 + [D]

160
Q

Therapeutic consequences of Drug-Response Curves

A

1) First part of curve is linear: at low doses, response increases in direct proportion to dose
2) Curve levels off at high drug doses: limit to the increase in response that can be achieved by increasing the drug dose

161
Q

Advantages of log-dose response curve (2)

A

1) Allows for wide range of doses to be plotted allowing easy comparison of different drugs
2) Dose-response relationship is nearly a straight line over range of therapeutic doses

162
Q

Potency

A

EC50 - concentration/dose required to produce 50% drugs max effect

represented on X-AXIS of dose-response curve

163
Q

Potency is dependent on __________ and _______

A

affinity (Kd) of receptors for binding drug

efficiency of drug-receptor complex to generate a response

164
Q

Max Efficacy (Emax)

A

Represented on Y-AXIS of dose-response curve (upper limit)

  • Indicates relationship between binding to receptor and ability to initiate a response
  • Most important determinant of drugs clinical utility
  • Efficacies of different drugs are compared even though they act at different receptors or targets
165
Q

Partial Agonist

A

occupy same receptor as full agonist, but bring about less than maximum response even at full dosage levels. (less efficacious)

166
Q

Full Agonist

A

occupy receptors and produce full or maximal response (produced by powerful agonists in tissue

167
Q

Agonist

A

drug that activates its receptor upon binding and brings about the characteristic tissue response

-effects efficacy of drug, NOT potency

168
Q

Antagonists

A

drug that inhibits the action of an agonist but has no effect in the absence of an agonist

  • Effect of antagonist depends on level of “normal tone” mediated by agonist in the tissue
  • An antagonist binds to the drug receptor, but is unable to bring about characteristic response
169
Q

Receptor Antagonists (aka?)

A

Pharmacologic antagonists

bind SAME receptor as the agonist

170
Q

Competitive reversible antagonist

A
  • Binds reversibly to active site of receptor
  • Blocks agonist from binding to receptor and maintains receptor in inactive conformation
  • Competes with agonist for receptor binding = reduces apparent agonist affinity for receptor (decrease potency)

Emax unchanged, EC50 increased, Potency decreased

171
Q

Non-competitive active site or allosteric antagonist

A
  • Binds irreversibly (covalently) or pseudoirreversibly (very high affinity) to the active site of receptor
  • Increasing concentration of agonist can NOT overcome antagonism - functional receptors “removed” from system

Emax reduced, no change on x axis (EC50), no change in potency

May see a shift to the right (decrease in apparent potency) if spare receptors available.

172
Q

Non-Receptor Antagonists include _____ and _______

A

physiological and chemical antagonists

173
Q

Physiological antagonists

A

activates or blocks a different receptor that mediates a physiologic response that is opposite to agonist

EX) Histamine –> biolgoical response
Epinephrine –> counteracts biological histamine response

174
Q

Chemical antagonists

A

does not involve receptor binding, antagonist acts to render agonist unable to interact with its receptor via modification or sequestration of agonist

175
Q

Adverse Drug Reactions

A

Response to a drug that is not desired, potentially harmful

-occurs at USUAL therapeutic doses

176
Q

Toxic reactions

A

occur at doses outside therapeutic range

177
Q

Graded dose-response curve

ED50 = ? (in this graph)

A

Individual subject, increasing the dose and measuring graded response for each dose

→ allows determination of the max effect of drug (Emax)

ED50 (50% max response in an individual)

178
Q

Population dose-response curve

ED50 = ? (in this graph)

A

characterize pharmacologic responses that are all-or-nothing events (not graded) in a population of subjects (not an individual)

ED50 = dose that initiates the response in 50% of the test population.

179
Q

Therapeutic index

A

compares midpoint in population

TI = LD50/ED50

higher TI = safer drug

180
Q

LD50

A

lethal dose that causes death in 50% of subjects

181
Q

TD50

A

dose that produces an undesirable side effect in 50% of subjects

182
Q

Standard Safety Margin

A

looks at the extremes in the population

SSM= [(LD1/ED99)-1] x 100

(ED99=response in 99% and LD1=toxic dose in 1%)

More conservative measure that TI, more reliable if pt response to therapy to specific drug varies, takes into account the extremes, SSM can be negative.

183
Q

Pharmacokinetic drug-drug interactions: when 2nd drug changes ________ of 1st drug

A

Plasma levels

184
Q

Pharmacodynamic drug-drug interactions includes ________ or _______ and does NOT change _____________

A

pharmacologic enhancement/antagonism OR physiologic enhancement/antagonism

NO changes in plasma concentration

185
Q

Methods to prevent/decrease absorption (4)

A

1) Gastric lavage
2) Activated charcoal
3) Osmotic cathartics
4) Emesis

186
Q

Gastric Lavage

A

washing of stomach contents with saline

  • Most rapid and complete method of emptying stomach
  • Problem is you only remove about 30% of most oral poisons with lavage + emesis
187
Q

Activated charcoal

A
  • binds drug in gut to limit absorption
  • Will also bind ipecac
  • Effective without prior gastric emptying
188
Q

Osmotic Cathartics

3 drugs used

A

empty bowel contents (laxative)

1) Magnesium citrate or sulfate
2) Sodium sulfate
3) Polyethylene glycol (Golyetyl)

189
Q

Emesis

2 drugs used

A

empties stomach contents rapidly

1) Syrup of Ipecac
2) Apomorphine

190
Q

Two drugs used to inhibit toxication

A

Ethanol (competitive inhibitor)

Fomepizole (specific inhibitor)

191
Q

Ethanol and Fomepizole act to…

A

inhibit alcohol dehydrogenase thus suppressing the production of toxic metabolites

-used to treat metanol and ethylene glycol toxicity

192
Q

Methanol and Ethylene Glycol toxication results due to…

A

conversion to toxic species by alcohol dehydrogenase

Methanol –> formic acid, formaldehyde

Ethylene glycol –> oxacilic acid

193
Q

Pharmacokinetic interventions available for treatment of drug overdoses/poisoning (5)

A

1) Prevent/Decrease Absorption
2) Inhibition of toxication
3) Enhancement of metabolism
4) Increase elimination of toxin
5) Antagonism of toxin action at target

194
Q

Acetaminophen normal metabolism

A

Most eliminated by phase II conjugation reaction (80-90%)

BUT phase I (CP2E1) enzymes (10%) converted to a hepatotoxic metabolite (detoxified by phase II conjugation)

195
Q

Metabolism of acetaminophen at toxic doses (> 10-20 g) (4 effects)

A

1) Saturate phase II metabolic pathways
2) Increased formation of phase I hepatotoxic metabolite
3) Depletion of glutathione stores for detoxification
4) Increased likelihood of hepatocellular injury

196
Q

Treatment of acetaminophen toxic dose (3)

A

gastric lavage
supportive therapy
N-acetylcysteine

197
Q

N-Acetylcysteine

A

Enhances toxic metabolite metabolism

precursor for glutathione synthesis

Acts as nucleophile to inactivate electrophilic hepatotoxic metabolite produced via acetaminophen metabolism

198
Q

________ is the phase I enzyme that converts 10% of acetaminophen to a hepatotoxic metabolite

A

CP2E1

199
Q

Acetaminophen and ethanol interaction (3)

A

3 strikes!

Ethanol induces CP2E1
Depletes glutothione
Is hepatotoxic on its own

200
Q

Hemodialysis

A

blood pumped through filter

  • Most effective for toxins with small Vd (large Vd = poorly removed b/c out of plasma) and low protein binding capacity
  • Effective for: methanol-ethylene glycol, salicylates, theophylline, Li+, ethanol
201
Q

Hemoperfusion

A

blood pumped through adsorbent column

For high molecular weight toxins with poor water solubility

202
Q

Forced diuresis can be accomplished with ________ or _________

A

normal saline (fluids)

Flurosemide (high efficacy diuretics)

203
Q

Toxicokinetics

A

Toxic dose of drug may alter “normal” pharmacokinetics

study of absorption, distribution and elimination of toxic parent compounds and metabolic products that aids in prediction of amount of toxin that reaches site of injury and resulting damage.

204
Q

Which types of drug studies involve testing drug efficacy?

A

Phase II and III

205
Q

Which types of drug studies involve testing drug safety?

A

Phase I, II, and III

206
Q

What is required for determining equivalence of generic drugs with their counterparts?

A

Pharmaceutical Equivalence and Bio-equivalence

Therapeutic equivalence is assumed if bio-equivalence is met

207
Q

3 criteria by which depressant and stimulant drugs and other drugs with abuse potential are classified

A

1) medical usefulness
2) abuse potential
3) physiological/physical dependence risk

208
Q

before meals

A

ac

209
Q

twice a day

A

bid

210
Q

at bedtime

A

hs

211
Q

after meals

A

pc

212
Q

when needed

A

prn

213
Q

every morning

A

qam

214
Q

immedietly

A

stat

215
Q

3 times a day

A

tid

216
Q

by mouth, orally

A

po

217
Q

per rectum, rectally

A

pr

218
Q

subcutaneous

A

sc-sq

219
Q

vaginally

A

vag

220
Q

where are drugs required to go THROUGH cells as apposed to between cells?

A

1) absorption of drug from small intestine
2) Diffusion of drug from blood to CSF
3) Absorption of drug from the kidneys

221
Q

Idiosynchratic reaction

A

occur elsewhere from the drug target in normal therapeutic doses

  • rare and unpredictable
  • EX) hepatotoxicity, allergic reactions
222
Q

Side effect

A

drug reaches target in the wrong system

  • dose dependent, predictable
  • EX) drowsiness with antihistamines
223
Q

Extension effect

A

drug acts on target system but and exceeds therapeutic doses

-dose dependent predictable

EX) bleeding/bruising with warfarin